Healthcare Use and Costs of Medium-chain Acyl-Coa Dehydrogenase Deficiency in Australia: Screening Versus No Screening

DSpace/Manakin Repository

Search OPUS


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Haas, M
dc.contributor.author Chaplin, M
dc.contributor.author Joy, P
dc.contributor.author Wiley, V
dc.contributor.author Black, C
dc.contributor.author Wilcken, B
dc.date.accessioned 2009-12-21T02:34:27Z
dc.date.issued 2007-08
dc.identifier.citation Journal of Pediatrics, 2007, 151 (2)
dc.identifier.issn 0022-3476
dc.identifier.other C1 en_US
dc.identifier.uri http://hdl.handle.net/10453/4704
dc.description.abstract Objective: To describe and analyze the use and costs of hospital services for children diagnosed with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency either with newborn screening or clinical diagnosis in Australia between 1994 and 2002. MCAD deficiency is a potentially lethal disorder of fatty-acid oxidation. Study design: We conducted a retrospective audit of medical records supplemented by a parental survey. Results: A total of 59 children with MCAD deficiency were identified, 24 by using newborn screening. In the first 4 years of life, screening children cost an average of $A1676 (US$1297) per year for inpatient, emergency department, and outpatient visits, compared with $A1796 (US$1390) for children in whom a clinical diagnosis was made. Forty-two percent of the children who underwent screening were admitted to the hospital, compared with 71% of children who did not undergo screening. Children who did not undergo screening used significantly more inpatient services and cost significantly more in emergency services. There were also some significant differences in use on a year-by-year basis. Conclusions: Children who do not undergo screening may be more likely to be admitted to the hospital and to incur higher emergency department costs than children who underwent screening, and children seem more likely to attend hospital outpatient clinics. Screening does not result in higher costs from a hospital perspective. © 2007 Mosby, Inc. All rights reserved.
dc.language eng
dc.relation.hasversion Accepted manuscript version
dc.relation.isbasedon 10.1016/j.jpeds.2007.03.011
dc.title Healthcare Use and Costs of Medium-chain Acyl-Coa Dehydrogenase Deficiency in Australia: Screening Versus No Screening
dc.type Journal Article
dc.description.version Published
dc.description.version Published
dc.parent Journal of Pediatrics
dc.journal.volume 2
dc.journal.volume 151
dc.journal.number 2 en_US
dc.publocation St Louis, USA en_US
dc.identifier.startpage 121 en_US
dc.identifier.endpage 126 en_US
dc.cauo.name BUS.Centre for Health Economics Research and Evaluation en_US
dc.conference Verified OK en_US
dc.for 1114 Paediatrics and Reproductive Medicine
dc.personcode 020119
dc.percentage 100 en_US
dc.classification.name Paediatrics and Reproductive Medicine en_US
dc.classification.type FOR-08 en_US
dc.location.activity United States
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Business
pubs.organisational-group /University of Technology Sydney/Strength - Health Economics and Research Evaluation
utslib.copyright.status Open Access
utslib.copyright.date 2015-04-15 12:23:47.074767+10
pubs.consider-herdc true


Files in this item

This item appears in the following Collection(s)

Show simple item record